Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Testicular cancer incidence predictions in Europe 2010–2035: A rising burden despite population ageing

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Tibolone and risk of gynecological hormone sensitive cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Does HPV status influence survival after vulvar cancer?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. DIAGNOSIS OF ENDOCRINE DISEASE: Sex steroid action in adolescence: too much, too little; too early, too late

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Nonalcoholic Fatty Liver Disease Impairs the Liver-Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. DaBlaCa-11: Photodynamic Diagnosis in Flexible Cystoscopy-A Randomized Study With Focus on Recurrence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. HPV-prevalence in elderly women in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
The bladder cancer genome harbors numerous oncogenic mutations and aberrantly methylated gene promoters. The aim of our study was to generate a profile of these alterations and investigate their use as biomarkers in urine sediments for noninvasive detection of bladder cancer. We systematically screened FGFR3, PIK3CA, TP53, HRAS, NRAS and KRAS for mutations and quantitatively assessed the methylation status of APC, ARF, DBC1, INK4A, RARB, RASSF1A, SFRP1, SFRP2, SFRP4, SFRP5 and WIF1 in a prospective series of tumor biopsies (N = 105) and urine samples (N = 113) from 118 bladder tumor patients. We also analyzed urine samples from 33 patients with noncancerous urinary lesions. A total of 95 oncogenic mutations and 189 hypermethylation events were detected in the 105 tumor biopsies. The total panel of markers provided a sensitivity of 93%, whereas mutation and methylation markers alone provided sensitivities of 72% and 70%, respectively. In urine samples, the sensitivity was 70% for all markers, 50% for mutation markers and 52% for methylation markers. FGFR3 mutations occurred more frequently in tumors with no methylation events than in tumors with one or more methylation events (78% vs. 33%; p <0.0001). FGFR3 mutation in combination with three methylation markers (APC, RASSF1A and SFRP2) provided a sensitivity of 90% in tumors and 62% in urine with 100% specificity. These results suggest an inverse correlation between FGFR3 mutations and hypermethylation events, which may be used to improve noninvasive, DNA-based detection of bladder cancer.
OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Vol/bind129
Udgave nummer1
Sider (fra-til)78-87
Antal sider10
ISSN0020-7136
DOI
StatusUdgivet - 1 jul. 2011

ID: 32311052